|
US20060078564A1
(en)
|
2002-05-08 |
2006-04-13 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
|
US6448035B1
(en)
|
1997-04-24 |
2002-09-10 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
|
|
DE60038675T2
(de)
*
|
1999-05-07 |
2009-07-02 |
Sanofi-Aventis Deutschland Gmbh |
Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
|
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
|
AU2001233003B2
(en)
*
|
2000-01-25 |
2006-02-09 |
Arca Biopharma, Inc. |
Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
|
|
KR20040028601A
(ko)
*
|
2000-09-05 |
2004-04-03 |
더 락커펠러 유니버시티 |
파골세포-관련 수용체
|
|
EP1453540A4
(en)
*
|
2001-11-14 |
2005-06-01 |
Immunex Corp |
MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US20050249723A1
(en)
*
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
EP1737890A2
(en)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
EP1799840A4
(en)
*
|
2004-09-03 |
2009-02-18 |
Univ Columbia |
ILT3-POLYPEPTIDES AND USES THEREOF
|
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
JP2010516769A
(ja)
*
|
2007-01-23 |
2010-05-20 |
ザイモジェネティクス， インコーポレイテッド |
炎症を軽減するための可溶性ＦｃγＲＩＡ
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
RU2529951C2
(ru)
|
2007-12-26 |
2014-10-10 |
Ксенкор, Инк. |
ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
JP2009201403A
(ja)
*
|
2008-02-27 |
2009-09-10 |
Tosoh Corp |
ヒト型Ｆｃレセプターをコードするポリヌクレオチド、およびそれを利用したヒト型Ｆｃレセプターの製造方法
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
BR112014000352A2
(pt)
|
2011-07-08 |
2017-02-14 |
Merck Sharp & Dohe Corp |
método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
|
|
EP2796144A1
(en)
*
|
2013-04-26 |
2014-10-29 |
SuppreMol GmbH |
Highly concentrated Formulations of soluble Fc receptors
|
|
JP6699085B2
(ja)
*
|
2015-03-25 |
2020-05-27 |
東ソー株式会社 |
Ｆｃ結合性タンパク質の精製方法
|
|
JP6808995B2
(ja)
*
|
2016-06-21 |
2021-01-06 |
東ソー株式会社 |
Ｆｃ結合性タンパク質の定量方法
|